EDITOR'S NOTE
LSL
LIFESCIENCELEADER.COM MARCH 2015
6
Raptor Pharmaceuticals compete for investor
ears and dollars during the same time slot
allotted for fireside chat participant John
Milligan, president and COO of one of the
hottest biopharma stocks on the planet —
Gilead Sciences.
March is the month when the Drug,
Chemica l & Associated Technologies
Association (DCAT) celebrates DCAT week,
March 16 to 19, which also takes place at the
Waldorf. Considered one of the largest gath-
erings in the world for the pharmaceutical
and related industries, DCAT week creates
peripheral networking and partnering
opportunities similar to JPM. For example,
Life Science Leader magazine hosts a small,
yet popular, gathering known as the annual
CMO Leadership Awards on Wednesday eve-
ning (March 18) at the "W" Hotel, which just
so happens to be right across the street from
the Waldorf.
The first quarter of 2015 also has been a
study in contrasts when it comes to which
companies we've featured on the cover of
Life Science Leader . January and February
featured executives from Pfizer and Astellas
— two of the biggest companies in two of the
biggest pharmaceutical markets in the world
(i.e., United States and Japan). This month,
though, we chose a smaller, less well-known,
family-owned business — Grünenthal. This
company has been doing business for over
70 years in the EU, the second largest
pharmaceutical market that's also one of the
most restrictive and challenging. Grünenthal
has traditionally conducted business with
partners. However, the company's chief sci-
entific officer, Klaus Langner, is seeking
to involve collaborators even earlier than
they have in the past. In the article on page
20, Langner shares how the German-based
company is building a new entrepreneurial
and networked approach to R&D;, which in
itself is an interesting study in biopharma
contrasts
. l
LIFE SCIENCE LEADER
5340 Fryling Rd., Suite 300
Erie, PA 16510-4672
Telephone: 814 897 7700
Fax: 814 899 4648
WWW.LIFESCIENCELEADER.COM
M A R CH 2 015 V O L . 7 N O. 3
he first quarter in the life sciences
industry provides a wonderful
study in contrasts. For example,
in January at the 33rd Annual J.P.
Morgan (JPM) Healthcare Conference, some
of the largest pharmaceutical and biotech
companies conduct presentations to packed
rooms at the Westin St. Francis. Meanwhile,
if you walk across Geary St. and into San
Francisco's famed Lefty O'Doul's Restaurant
& Cocktail lounge, you will see some of bio-
pharma's start-up CEOs conducting multiple
meetings in an effort to find funds to fuel
their proprietorships. At the same time, at
the Parc 55 Wyndham on Cyril Magnin, the
Biotech Showcase conference is happening.
While Shire's CEO, Flemming Ornskov, M.D.,
presents for 25 minutes at JPM in a room that
can hold 1,100, at the showcase, Immunocore
Limited's chief business officer, Eva-Lotta
Allan, has 15 minutes to convince a room that
would burst with 30 people why they should
partner and/or invest in her clinical-stage
company.
Februar y brings you from the warm
weather of the West Coast to the blustery
East. The city that never sleeps, New York,
plays host to the seventeenth BIO CEO &
Investor Conference at the Waldorf Astoria.
Boasting 1,400+ attendees from 26 different
countries, lesser-known companies like
Synthetic Biologics, Durect, Adocia, and
VP OF PUBLISHING
Jon Howland / Ext. 203
jon.howland@lifescienceconnect.com
CHIEF EDITOR
Rob Wright / Ext. 140
rob.wright@lifescienceconnect.com
EXECUTIVE EDITORS
Wayne Koberstein
wayne.koberstein@lifescienceleader.com
Louis Garguilo
louis.garguilo@lifescienceconnect.com
Ed Miseta
ed.miseta@lifescienceconnect.com
Trisha Gladd
trisha.gladd@lifescienceconnect.com
EDITORIAL DIRECTOR
Dan Schell / Ext. 284
dan.schell@lifescienceleader.com
SENIOR DIRECTOR OF PUBLISHING
Perry Rearick
perry.rearick@lifescienceconnect.com
MARKET DIRECTOR
Robert Wilson
robert.wilson@lifescienceconnect.com
PRODUCT DIRECTOR
Jenell Skemp
jenell.skemp@lifescienceconnect.com
PROJECT MANAGER
Megan Rainbow
megan.rainbow@lifescienceconnect.com
DIRECTOR, LIFE SCIENCE TRAINING
INSTITUTE
Bill Beyer
bill.beyer@lifescienceconnect.com
PUBLISHER, CLINICAL
& CONTRACT RESEARCH
Sean Hoffman
724 940 7557 / Ext. 165
sean.hoffman@lifescienceconnect.com
PUBLISHER/BIOPHARM & LAB
Shannon Primavere / Ext. 279
shannon.primavere@lifescienceconnect.com
PUBLISHER/OUTSOURCING
Cory Coleman / Ext. 108
cory.coleman@lifescienceconnect.com
GROUP PUBLISHER/OUTSOURCING
Ray Sherman / Ext. 335
ray.sherman@lifescienceconnect.com
BUSINESS DEVELOPMENT MANAGER
Mike Barbalaci / Ext. 218
mike.barbalaci@lifescienceconnect.com
SR. ACCOUNT EXECUTIVE
Scott Moren / Ext. 118
scott.moren@lifescienceconnect.com
PRODUCTION DIRECTOR
Lynn Netkowicz / Ext. 205
lynn.netkowicz@jamesonpublishing.com
MANAGE SUBSCRIPTIONS
814 897 9000 / Ext. 315
subscriptions@jamesonpublishing.com
@
RFWrightLSL
linkedin.com/in/robertfwright pinterest.com/rfwrightlsl
facebook.com/LifeScienceLeader
Ever Notice How Q1 In
Biopharma Provides A
Study In Contrasts?
R O B W R I G H T Chief Editor
T